Macrotope

Executive Summary

Macrotope is a US-based biotechnology company leveraging its proprietary MacroAntigen Vaccine (MAV™) discovery engine to advance therapeutic antibody discovery and next-generation vaccine development. Founded in 2018 and headquartered in San Francisco, the company employs an antigen-centric approach that engineers antigen conformational dynamics to elicit broader and more potent immune responses. This platform is designed to generate superior antibodies and vaccines with improved manufacturability and global deployability, positioning Macrotope as a potential leader in the rapidly evolving fields of antibody engineering and vaccinology. The company's strategy focuses on internal pipeline development as well as potential partnerships with pharmaceutical firms seeking novel biologics. The MAV platform's ability to unlock difficult targets and produce robust immune responses could drive significant value, particularly in areas with high unmet medical need such as infectious diseases and oncology. While Macrotope remains at a relatively early stage, its differentiated technology and experienced team provide a strong foundation for future growth. Key near-term milestones include advancing lead candidates toward the clinic and securing strategic collaborations. If successful, the platform could generate multiple product candidates and become a valuable asset in the biotech landscape. The company's progress over the next 12-18 months will be critical in validating its technology and establishing its market position.

Upcoming Catalysts (preview)

• Q3 2026First strategic partnership for MAV platform70% success
• Q4 2026Preclinical proof-of-concept data for lead antibody candidate60% success
• H1 2027IND filing for first therapeutic program50% success